BRPI0713447A2 - composição forma de dosagem oral sólida, e, método para o tratamento de dor - Google Patents
composição forma de dosagem oral sólida, e, método para o tratamento de dor Download PDFInfo
- Publication number
- BRPI0713447A2 BRPI0713447A2 BRPI0713447-9A BRPI0713447A BRPI0713447A2 BR PI0713447 A2 BRPI0713447 A2 BR PI0713447A2 BR PI0713447 A BRPI0713447 A BR PI0713447A BR PI0713447 A2 BRPI0713447 A2 BR PI0713447A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- dosage form
- oral dosage
- solid oral
- hydrocodone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 abstract 4
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 abstract 4
- 229960000240 hydrocodone Drugs 0.000 abstract 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 4
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 abstract 4
- 230000002902 bimodal effect Effects 0.000 abstract 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 abstract 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 abstract 1
- 229960002009 naproxen Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSIçãO, FORMA DE DOSAGEM ORAL SóLIDA, E, MéTODO PARA O TRATAMENTO DE DOR. A invenção diz respeito a composições compreendendo uma composição de naproxeno nanoparticulada em combinação com uma composição de hidrocodona de liberação modificada multiparticulada que, mediante administração a um paciente, distribui uma hidrocodona de uma maneira bimodal ou multimodal. A composição de liberação modificada multiparticulada compreende um primeiro componente e pelo menos um componente subseqúente, o primeiro componente compreendendo uma primeira população de partículas compreendendo hidrocodona e o pelo menos um componente subseqúente compreendendo uma segunda população de partículas compreendendo hidrocodona, em que a combinação dos componentes apresenta um perfil de liberação bimodal ou multimodal. A invenção também diz respeito a uma forma de dosagem oral sólida compreendendo uma composição de combinação como esta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81588506P | 2006-06-23 | 2006-06-23 | |
| US60/815885 | 2006-06-23 | ||
| PCT/US2007/072052 WO2007150074A2 (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0713447A2 true BRPI0713447A2 (pt) | 2012-03-13 |
Family
ID=38834446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0713447-9A BRPI0713447A2 (pt) | 2006-06-23 | 2007-06-25 | composição forma de dosagem oral sólida, e, método para o tratamento de dor |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2032137A2 (pt) |
| JP (1) | JP2009541359A (pt) |
| KR (1) | KR20090024284A (pt) |
| CN (1) | CN101484170A (pt) |
| AU (1) | AU2007260821B2 (pt) |
| BR (1) | BRPI0713447A2 (pt) |
| CA (1) | CA2660649A1 (pt) |
| IL (1) | IL196065A0 (pt) |
| MX (1) | MX2008016223A (pt) |
| NO (1) | NO20090158L (pt) |
| WO (1) | WO2007150074A2 (pt) |
| ZA (1) | ZA200810221B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
| NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
| WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
| EP2826467B1 (en) | 2010-12-22 | 2017-08-02 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| CN105120846B (zh) | 2013-02-05 | 2019-10-18 | 普渡制药公司 | 抗篡改的药物制剂 |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| EP3355865B8 (en) | 2015-09-29 | 2025-02-19 | Merz Pharmaceuticals, LLC | Sustained release compositions of 4-aminopyridine |
| CN112500694B (zh) * | 2020-12-04 | 2022-03-29 | 东莞威赢高尔夫用品有限公司 | 一种电子设备贴皮材料及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
| CA2348871C (en) * | 1998-11-02 | 2009-04-14 | John G. Devane | Multiparticulate modified release composition |
| US7713551B2 (en) * | 2002-09-11 | 2010-05-11 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
-
2007
- 2007-06-25 KR KR1020097001439A patent/KR20090024284A/ko not_active Withdrawn
- 2007-06-25 CN CNA2007800236169A patent/CN101484170A/zh active Pending
- 2007-06-25 WO PCT/US2007/072052 patent/WO2007150074A2/en not_active Ceased
- 2007-06-25 EP EP07799011A patent/EP2032137A2/en not_active Withdrawn
- 2007-06-25 BR BRPI0713447-9A patent/BRPI0713447A2/pt not_active IP Right Cessation
- 2007-06-25 CA CA002660649A patent/CA2660649A1/en not_active Abandoned
- 2007-06-25 AU AU2007260821A patent/AU2007260821B2/en not_active Expired - Fee Related
- 2007-06-25 JP JP2009516756A patent/JP2009541359A/ja active Pending
- 2007-06-25 MX MX2008016223A patent/MX2008016223A/es not_active Application Discontinuation
-
2008
- 2008-12-02 ZA ZA200810221A patent/ZA200810221B/xx unknown
- 2008-12-18 IL IL196065A patent/IL196065A0/en unknown
-
2009
- 2009-01-12 NO NO20090158A patent/NO20090158L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101484170A (zh) | 2009-07-15 |
| MX2008016223A (es) | 2009-01-19 |
| AU2007260821A1 (en) | 2007-12-27 |
| JP2009541359A (ja) | 2009-11-26 |
| KR20090024284A (ko) | 2009-03-06 |
| WO2007150074A2 (en) | 2007-12-27 |
| IL196065A0 (en) | 2009-09-01 |
| ZA200810221B (en) | 2009-11-25 |
| EP2032137A2 (en) | 2009-03-11 |
| CA2660649A1 (en) | 2007-12-27 |
| NO20090158L (no) | 2009-03-20 |
| AU2007260821B2 (en) | 2012-06-21 |
| WO2007150074A3 (en) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125077T1 (el) | Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3 | |
| BR122019016628B8 (pt) | uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular | |
| BRPI0910198A2 (pt) | composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo. | |
| BRPI0909768A2 (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto | |
| BRPI0717697A2 (pt) | composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos | |
| BRPI0717845A2 (pt) | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos | |
| WO2007109192A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| BRPI0816814A2 (pt) | composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação. | |
| BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
| BR112012001297A2 (pt) | conector. | |
| WO2007109172A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| BRPI0819799A2 (pt) | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença | |
| BRPI0918194A2 (pt) | ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
| BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
| WO2007109154A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2007109160A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| BRPI1008974A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3 | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
| UY30468A1 (es) | Compuestos quimicos. | |
| WO2010071826A3 (en) | Methods for treating osteoclast-related disease, compounds and compositions thereof | |
| WO2007109182A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2007109201A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE. |